Oxaliplatin (NSC 266046)

For research use only.

Catalog No.S1224 Synonyms: L-OHP, Eloxatin

123 publications

Oxaliplatin (NSC 266046) Chemical Structure

CAS No. 61825-94-3

Oxaliplatin (NSC 266046, L-OHP, Eloxatin) is a DNA alkylating agent that activates autophagy. Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells. DMF is recommended for dissolution. Solutions are best fresh-prepared.

Selleck's Oxaliplatin (NSC 266046) has been cited by 123 publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Oxaliplatin (NSC 266046, L-OHP, Eloxatin) is a DNA alkylating agent that activates autophagy. Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells. DMF is recommended for dissolution. Solutions are best fresh-prepared.
Features This product is not recommended to be dissolved in dimethylsulfoxide (DMSO).[9]
Targets
DNA synthesis [1]
(RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, HT-144 cells)
In vitro

The main mechanism of action of Oxaliplatin is mediated through the formation of DNA–adducts. Oxaliplatin induces primary and secondary DNA lesions that lead to cell apoptosis. [1] Oxaliplatin is active against human melanoma cell lines C32 and G361 with IC50 of 0.98 mM and 0.14 mM, respectively. [2] Oxaliplatin effectively inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC50 of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Caco2 MV;GeY5kfGmxbjDBd5NigQ>? MWmzNE8yODEEoN88US=> NF\J[|YyPsLiaB?= NHnNdZZFVVOR NFexeGRi[3SrdnH0[ZMhVnKoMh?= MnXaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3NU[0NVUoRjJ2NUW2OFE2RC:jPh?=
Caco2  MYfGeY5kfGmxbjDBd5NigQ>? M3z1SVMwOTBxM{Cg{txO NGW4W4EyPiCq Mon2SG1UVw>? NUDocIR3cW6lcnXhd4V{KHSqZTDtVm5CKGyndnXsd{Bw\sLiQVvSNWMyNCCQUV:xMEBJVy1zLDDNVnAzNMLiYX7kUXJRO8LiZH;z[U1l\XCnbnTlcpRtgQ>? MmrWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3NU[0NVUoRjJ2NUW2OFE2RC:jPh?=
Caco2  NVXy[G5xTnWwY4Tpc44hSXO|YYm= M2L3dlMxyqEQvF2= M4DQR|I1KGh? MYfEUXNQ M3rSdIlv\HWlZYOgeIhmKGW6cILld5Nqd25ib3[gTG8uOSxiQVvSNWMtKGGwZDDOVW8y Mln4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3NU[0NVUoRjJ2NUW2OFE2RC:jPh?=
SW620 NYXOe5NnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\wRWIyOC15MDDt[{9N MknrNlQwPDhxN{KgbC=> MV\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M1iyVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkS2N|A2Lz5{NE[0OlMxPTxxYU6=
SW480  NIj5S5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPmdZI1QCCqwrC= NWiwZ2JIUUN3ME2yNE45KHWpL33M MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd{ME[3OUc,OjR5MkC2O|U9N2F-
HCT116 NVnpN3FsTnWwY4Tpc44hSXO|YYm= MnXENk82KML3TR?= M17VWVI1NzR6IHi= NYfreZVDe3WycILld5NmeyC|dYL2bZZqdiCvUl7BJIV5eHKnc4Ppc44> MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd4MUSxNUc,OjR5NkG0NVE9N2F-
HT-29 NWrpNZd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjTdXRuOcLizszN MYCwMVczKGh? NVjyW2xVcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUB1cW2nIHTldIVv\GWwdDDtZY5v\XJ? MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl7N{S1NUc,OjR7OUe0OVE9N2F-
SW480 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\qb|HDqM7:TR?= NYDxZ2U3OC15MjDo NXfDSm53cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUB1cW2nIHTldIVv\GWwdDDtZY5v\XJ? MkLGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUe0OVEoRjJ2OUm3OFUyRC:jPh?=
HUVEC MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XRO2lEPTB;MUGuN|DDqMLzwrCxMlAzKM7:TR?= NIHFU4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOwO|Q1QCd-MkWzNFc1PDh:L3G+
HEK293 NXniWmRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3hSJZWUUN3ME24MlgzyqEEsdMgOU42QSEQvF2= Mn\DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|MEe0OFgoRjJ3M{C3OFQ5RC:jPh?=
HT-29 MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnlV3ZKSzVyPkWwJO69VQ>? M3u1clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{C3OFQ5Lz5{NUOwO|Q1QDxxYU6=
HCT-116 M3vDfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvzTWM2OD14LkK0xsDDucLiMj65O{DPxE1? MlnRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|MEe0OFgoRjJ3M{C3OFQ5RC:jPh?=
MCF-7 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvXU3A3UUN3ME2xOE4zPMLiwsJCpFEvQDJizszN M1zU[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{C3OFQ5Lz5{NUOwO|Q1QDxxYU6=
HepG2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIKzN2NKSzVyPUG0MlI1yqEEsdMgNU45OiEQvF2= NHHJe5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOwO|Q1QCd-MkWzNFc1PDh:L3G+
A549 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;Ib2ZNUUN3ME21NU4xQMLiwsJCpFExNjl4IN88US=> MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNyN{S0PEc,OjV|MEe0OFg9N2F-
SGC7901 M4Hid2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzjbYExUUN3ME2yNU44O8LiwsJCpFMvODhizszN MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNyN{S0PEc,OjV|MEe0OFg9N2F-
COC1 NIfZcZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXX6O3U{UUN3ME20Ok4zOMLiwsJCpFMvOTRizszN MlvZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|MEe0OFgoRjJ3M{C3OFQ5RC:jPh?=
HCT116  MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlL1O|IhcMLi NHq0cFNKSzVyPU[uNlPDuTBwN{WgxtVoN22O MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN4ME[zNUc,OjV|NkC2N|E9N2F-
SW480 NGnGPXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HteVczKGkEoB?= NVHSNmlHUUN3ME2xNE44yrF{LkK2JOK2\y:vTB?= MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN4ME[zNUc,OjV|NkC2N|E9N2F-
MIAPaCa-2 M2rTdmZ2dmO2aX;uJGF{e2G7 NVXlNJBCOjYkgJpCuW0> MWqyOE81QCCq NXfOT5d[cW6mdXPld{BkdGWjdnHn[UBw\iCSQWLQMEBk[XOyYYPlMVktKGOjc4Dhd4UuQCCjbnSgZ4F{eGG|ZT2zxsA> MoTJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NES5NVQoRjJ3NES0PVE1RC:jPh?=
Panc-1 M1rxXGZ2dmO2aX;uJGF{e2G7 NXjiUnZKOjYkgJpCuW0> MVyyOE81QCCq MnTDbY5lfWOnczDjcIVifmGpZTDv[kBRSVKSLDDjZZNx[XOnLUmsJINie3Cjc3WtPEBidmRiY3HzdIF{\S1|wrC= Mm\TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NES5NVQoRjJ3NES0PVE1RC:jPh?=
MIAPaCa-2 MnrkRZBweHSxc3nzJGF{e2G7 MWOyOgKBkcL3TR?= MYiyOEBp NWi0fW9[cW6mdXPld{BieG:ydH;zbZMhcW5iYTDzfY5memerc4TpZ{Bu[W6wZYKgZ49u[mmwZXSge4l1cCCZQR?= NGHado89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS0OFkyPCd-MkW0OFQ6OTR:L3G+
Panc-1 M4rNU2Fxd3C2b4Ppd{BCe3OjeR?= M1fSb|I26oDLwsXN NXruSnpmOjRiaB?= MlLEbY5lfWOnczDhdI9xfG:|aYOgbY4h[SC|eX7ldodqe3SrYzDtZY5v\XJiY3;tZolv\WRid3n0bEBYSQ>? M1nQVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NES0PVE1Lz5{NUS0OFkyPDxxYU6=
HPDE MUXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NFv0U4gzPS93MDFOwG0> NUjRZVF4OjRxNEigbC=> MmLLbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCxZjDQR{Bk\WyuczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC MlzzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NES5NVQoRjJ3NES0PVE1RC:jPh?=
SW1990 M2HUOmNmdGxiVnnhZoltcXS7IFHzd4F6 NWX1SGV7OjVxNUCg{txO MmjyNlQwPDhiaB?= NUDI[2VXcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDv[kBRSyClZXzsd{BqdiCjIIP5coVz\2m|dHnjJI1idm6ncjDjc41jcW6nZDD3bZRpKFeD M2jMbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NES0PVE1Lz5{NUS0OFkyPDxxYU6=
MIAPaCa-2 MVTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MmL5NlUwPTBizszN NIfTUpYzPC92ODDo Ml[2bY5pcWKrdIOgdJJwdGmoZYLheIlwdiCxZjDQR{Bk\WyuczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC MlvVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NES5NVQoRjJ3NES0PVE1RC:jPh?=
Panc-1 MXHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NYHMV5hnOjVxNUCg{txO NULyPVFWOjRxNEigbC=> MmrabY5pcWKrdIOgdJJwdGmoZYLheIlwdiCxZjDQR{Bk\WyuczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR2NEmxOEc,OjV2NES5NVQ9N2F-
A549/CDDP NYrk[nNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17aU2lEPTB;MUiuOkDDuSBzLkKg{txO MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ{NUK0N{c,OjV4MkWyOFM9N2F-
A549 NGHoZZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTVwODFCtUAxNjZizszN MkGxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MkWyOFMoRjJ3NkK1NlQ{RC:jPh?=
SW480 NXK0UnU4TnWwY4Tpc44hSXO|YYm= NX63XoFLOTEkgJpCuYcwdWx? NWfBV3RwOjUkgJno MUnlcohidmOnczDj[YxtfWyjcjDheZRweGijZ3njJIZtfXh? NXz2bpRxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OFk1OjBpPkK1O|Q6PDJyPD;hQi=>
SW620 Moe1SpVv[3Srb36gRZN{[Xl? NIjEWJoyOOLCidM1[{9udA>? NYrvPGtYOjUkgJno NFHBU3ZmdmijbnPld{Bk\WyudXzhdkBifXSxcHjh[4lkKG[udYi= NF2ySVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe0PVQzOCd-MkW3OFk1OjB:L3G+
SW480 M1;QUGZ2dmO2aX;uJGF{e2G7 NWf0N2UzOTEkgJpCuYcwdWx? NEPuV3czPOLCiXi= MoPXbY5kemWjc3XzJGxEOy2LSTDhZ4N2dXWuYYTpc44h[W6mIHTlZ5Jm[XOnczDQOlIh\XiycnXzd4lwdg>? NHficlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe0PVQzOCd-MkW3OFk1OjB:L3G+
SW620 M3v5N2Z2dmO2aX;uJGF{e2G7 M3zrU|Ex6oDLwsXnM41t M4jqeFI16oDLaB?= NYnGVVFxcW6lcnXhd4V{KEyFMz3JTUBi[2O3bYXsZZRqd25iYX7kJIRm[3KnYYPld{BRPjJiZYjwdoV{e2mxbh?= M3Hm[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{S5OFIxLz5{NUe0PVQzODxxYU6=
HT-29 M2L5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV6zb49{UUN3ME21MlIzKM7:TR?= NV\GXHVPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OlE1PzlpPkK1O|YyPDd7PD;hQi=>
SNU-175 Mlr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\WTWM2OD1zLkWxJO69VQ>? NUHvUpJRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OlE1PzlpPkK1O|YyPDd7PD;hQi=>
COLO-320DM NH\6N4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjXTWM2OD13LkO4JO69VQ>? MnK2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkG0O|koRjJ3N{[xOFc6RC:jPh?=
DLD-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\HbXJqUUN3ME24MlY2KM7:TR?= M4\1RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{[xOFc6Lz5{NUe2NVQ4QTxxYU6=
DiFi NWrIO5J2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfBTWM2OD1zMD65OUDPxE1? MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd4MUS3PUc,OjV5NkG0O|k9N2F-
HCT-15 MmTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRThwNkSg{txO NFjwPG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2NVQ4QSd-MkW3OlE1Pzl:L3G+
SCM-1 MojxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDBN5RKSzVyPUG3MlUh|ryP NITPZ3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe4PVA2Pyd-MkW3PFkxPTd:L3G+
TMK-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnZSHNYUUN3ME2yNk43KM7:TR?= NF7mSIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe4PVA2Pyd-MkW3PFkxPTd:L3G+
MKN-45 MlLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmL5TWM2OD1zND6wJO69VQ>? NVrDVW1ZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3PFkxPTdpPkK1O|g6ODV5PD;hQi=>
AGS MmfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\4TWM2OD1zMD62JO69VQ>? NFnxT5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe4PVA2Pyd-MkW3PFkxPTd:L3G+
S3 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXLSmVTUUN3ME21N{42KMLzIEGuOUDPxE1? NXzQbWtnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NFExODdpPkK1PFAyODB5PD;hQi=>
SiHa NWjTVZFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTBwODFCtUAxNjFizszN Mm\YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MEGwNFcoRjJ3OECxNFA4RC:jPh?=
HT-29 NILCZ|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTN3Lk[g{txO NWLtdW03RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNFMxQDVpPkK2NFA{ODh3PD;hQi=>
DLD-1 M1fHPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYezXGpPUUN3ME2zNk4zKM7:TR?= Moi2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMEOwPFUoRjJ4MECzNFg2RC:jPh?=
HT29 NWXZd3NLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nmb2lEPTB;NkOg{txOKMLzIEG4 M{Lhc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEC0NFg1Lz5{NkCwOFA5PDxxYU6=
MC38 M3XCRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVH6UZJ5UUN3ME2yN{DPxE1iwsGgNi=> M4XNdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEC0NFg1Lz5{NkCwOFA5PDxxYU6=
SW620 M3LKPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPwTWM2OD1|Lk[4JO69VQ>? NEiyRlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyN|A5PSd-Mk[wNlMxQDV:L3G+
SW480 NX3mPGV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2OyRWlEPTB;Mj64OkDPxE1? M{T4TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN|A5PTxxYU6=
RKO MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTFwMkOg{txO MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB{M{C4OUc,OjZyMkOwPFU9N2F-
LoVo MlK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTFwMjFOwG0> M2S1dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN|A5PTxxYU6=
KM12 MlfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2D1RWlEPTB;ND6zO{DPxE1? MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB{M{C4OUc,OjZyMkOwPFU9N2F-
HCT116p53- M4HEWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXUTWM2OD1zLkC4JO69VQ>? MmnPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMkOwPFUoRjJ4MEKzNFg2RC:jPh?=
HCT116 M4GwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLN[oI2UUN3ME2xMlA1KM7:TR?= M{jiTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN|A5PTxxYU6=
HCT15 NGPZNoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTFwNEOg{txO M4KzclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN|A5PTxxYU6=
HT29 M4jsWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTJwNkmg{txO M1\2b|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN|A5PTxxYU6=
DLD1 Mn:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTJwMEGg{txO NVvZPHBWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlMxQDVpPkK2NFI{ODh3PD;hQi=>
Colo205 NGWwVWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjoTWM2OD1|LkOzJO69VQ>? Mn7ZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMkOwPFUoRjJ4MEKzNFg2RC:jPh?=
BE MnHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHMTWM2OD1|LkOzJO69VQ>? NFq0UFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyN|A5PSd-Mk[wNlMxQDV:L3G+
CT26  NWntemZiS2WubDDWbYFjcWyrdImgRZN{[Xl? M2PNU|QhdU1? MoDLOFghcMLi Mn[w[IVkemWjc3XzJINmdGxidnnhZoltcXS7IITvJFU{NjJn MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF|N{CxNkc,OjZzM{ewNVI9N2F-
CT26  NWnkdFFGTnWwY4Tpc44hSXO|YYm= NITTbnQ1KG2P MmD5OFghcMLi Ml:ybY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVteyCxZjDheZRweGijZ4mtdoVt[XSnZDDwdo91\Wmwczygd5VkcCCjczDMR|MuUUluIFLlZ4xqdjFiYX7kJGFVTzV? NFXibZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzO|AyOid-Mk[xN|cxOTJ:L3G+
CT26  NXnzXXJLTnWwY4Tpc44hSXO|YYm= NHTQTFg1KG2P NFm4NVU1QCCqwrC= M1LLVIlv\HWlZYOgZZV1d3CqYXf5 MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF|N{CxNkc,OjZzM{ewNVI9N2F-
SK-OV-3 M3XEV2Z2dmO2aX;uJGF{e2G7 NFHUTYY2OCEQvF5CpC=> NFHEPVY1QCCqwrC= NFTnepdxem:vb4Tld{B{\W6|aYTpeol1gSCxZjDveoFzcWGwIHPhdoNqdm:vYTD0c{BPUyClZXzsMY1m\GmjdHXkJIN6fG:ueYPpdy=> M2\1OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO4OlcyLz5{NkGzPFY4OTxxYU6=
OVCAR-5 MXrGeY5kfGmxbjDBd5NigQ>? M4jR[FIxKM7:TdMg MVuyOIg> NFS0SIVxem:vb4Tld{B{\W6|aYTpeol1gSCxZjDveoFzcWGwIHPhdoNqdm:vYTD0c{BPUyClZXzsMY1m\GmjdHXkJIN6fG:ueYPpdy=> MoXQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{i2O|EoRjJ4MUO4OlcyRC:jPh?=
PA-1 MYLGeY5kfGmxbjDBd5NigQ>? NUfmdYlHOTBizszNxsA> MYiyOIg> M1TkepBzd22xdHXzJJNmdnOrdHn2bZR6KG:oIH;2ZZJq[W5iY3HyZ4lvd22jIITvJG5MKGOnbHytcYVlcWG2ZXSgZ5l1d2y7c3nz MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF|OE[3NUc,OjZzM{i2O|E9N2F-
SK-OV-3 NWT1SHFXTnWwY4Tpc44hSXO|YYm= NUezTIVKPTBizszN NHTnPWg6PiCq NX3MdpUxfXBvcnXneYxifGW|IITo[UB{fHKnc4OgcIlo[W6mczDmc5IhVktiY3XscE1i[3SrdnH0bY5oKHKnY3XweI9zeyCjbnSgWHJCUUxicnXj[ZB1d3K| M2ThdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO4OlcyLz5{NkGzPFY4OTxxYU6=
OVCAR-5 MXfGeY5kfGmxbjDBd5NigQ>? M{nCRVMxKM7:TR?= NGiwO5g1QGh? NEDFUWF2eC2{ZXf1cIF1\XNidHjlJJN1emW|czDsbYdidmS|IH\vdkBPUyClZXzsMYFkfGm4YYTpcochemWlZYD0c5J{KGGwZDDUVmFKVCC{ZXPldJRwenN? MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF|OE[3NUc,OjZzM{i2O|E9N2F-
PA-1 MVLGeY5kfGmxbjDBd5NigQ>? MmnYNVAh|ryPwrC= MkLqOFhp M1r1TpVxNXKnZ4XsZZRmeyC2aHWgd5Rz\XO|IHzp[4Fv\HNiZn;yJG5MKGOnbHytZYN1cX[jdHnu[{Bz\WOncITvdpMh[W6mIGTSRWlNKHKnY3XweI9zew>? MljQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{i2O|EoRjJ4MUO4OlcyRC:jPh?=
SK-OV-3 MYTGeY5kfGmxbjDBd5NigQ>? MYK1NEDPxE1? MYS5OkBp Ml\neJJq\2encnXzJJRp\SCycn;keYN1cW:wIH;mJJR6eGViSTDJSm5{KGGwZDDjbIVud2urbnXz M3nkcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO4OlcyLz5{NkGzPFY4OTxxYU6=
OVCAR-5 MWDGeY5kfGmxbjDBd5NigQ>? MnzlN|Ah|ryP M{TOU|Q5cA>? MlnJeJJq\2encnXzJJRp\SCycn;keYN1cW:wIH;mJJR6eGViSTDJSm5{KGGwZDDjbIVud2urbnXz NF7yWoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzPFY4OSd-Mk[xN|g3PzF:L3G+
PA-1 M1P5[GZ2dmO2aX;uJGF{e2G7 MkLVNVAh|ryPwrC= NYjU[lVZOjSq M4TjRpRzcWepZYLld{B1cGVicILv[JVkfGmxbjDv[kB1gXCnIFmgTWZPeyCjbnSgZ4hmdW:taX7ldy=> NYfZTGdPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN|g3PzFpPkK2NVM5PjdzPD;hQi=>
SK-OV-3 NHfscIVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NHzVVIQxNTFyMDFOwG0> NHHkV2gzPC92OD:3NkBp NHSwVJFqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NEHRNVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzPFY4OSd-Mk[xN|g3PzF:L3G+
OVCAR-5 M{WwZWNmdGxiVnnhZoltcXS7IFHzd4F6 NHTKU4UxNTZyIN88US=> MV:yOE81QC95MjDo MmPJbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF|OE[3NUc,OjZzM{i2O|E9N2F-
PA-1 Mk\nR4VtdCCYaXHibYxqfHliQYPzZZk> M{joWlAuOjBizszN NI\mVZAzPC92ODDo NFzPemNqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF|OE[3NUc,OjZzM{i2O|E9N2F-
HCT116 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTpU5NOUUN3ME2wMlQyyqEEsdMgNE4xOiEQvF2= M{jXSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUS4OVk3Lz5{NkG0PFU6PjxxYU6=
HT29 NYC1emE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI[zdJZKSzVyPUCuPFjDqMLzwrCwMlIh|ryP M2\wUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUS4OVk3Lz5{NkG0PFU6PjxxYU6=
SNU-387 Mni4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\BeGNKSzVyPUK1xsDDucLiMj63JO69VQ>? MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF4MESyPUc,OjZzNkC0Nlk9N2F-
SNU-475 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjWSZFWUUN3MP-8olMxKM7:TR?= M1jxd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MU[wOFI6Lz5{NkG2NFQzQTxxYU6=
Hep-G2 NFi2R5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkO5TWM2OD1zMz6xxsDDucLiMT62JO69VQ>? M2K4XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MU[wOFI6Lz5{NkG2NFQzQTxxYU6=
SNU-398 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPZUHhKSzVyPU[uOeKhyrIEoEGuNUDPxE1? NFzuNIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkG2NFQzQSd-Mk[xOlA1Ojl:L3G+
LoVo  MX\GeY5kfGmxbjDBd5NigQ>? M2jCUVEwPSEQvF2= M3XFUVI1NzR6IHi= Mn7WbY5lfWOnczD0doFve2O{aYD0bY9v[WxicnXwdoV{e2mxbjDv[kBFXVRvTh?= M2nhNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkC4OVI{Lz5{NkKwPFUzOzxxYU6=
HCT116 p53+/+ M1;5SGZ2dmO2aX;uJGF{e2G7 NUnNZoNnOS93IN88US=> NXXKRW5SOjRxNEigbC=> MmDkbY5lfWOnczD0doFve2O{aYD0bY9v[WxicnXwdoV{e2mxbjDv[kBFXVRvTh?= NFqzXnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkKwPFUzOyd-Mk[yNFg2OjN:L3G+
MDA-MB-231 NITjTINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDYWpZKSzVyPUKzMlEhyrFiMD6xJO69VQ>? MmDFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{MUG1PVEoRjJ4MkGxOVkyRC:jPh?=
MCF-7 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDqcVRKSzVyPUG1MlQhyrFiMD6zJO69VQ>? NFrO[o49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkKxNVU6OSd-Mk[yNVE2QTF:L3G+
SK-BR-3 M1[xWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTXTWM2OD1|MT6wJOKyKDBwMTFOwG0> MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJzMUW5NUc,OjZ{MUG1PVE9N2F-
LoVo MlPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWO0PEBpyqB? MW\JR|UxRTl2LkizJO69VQ>? MlTVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{Nkm3OVkoRjJ4Mk[5O|U6RC:jPh?=
HCT116 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPaOFghcMLi MXPJR|UxRTFzLki2JO69VQ>? Mny3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{Nkm3OVkoRjJ4Mk[5O|U6RC:jPh?=
SW480 NEOzfllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HVRVQ5KGkEoB?= MnP2TWM2OD1zLki3JO69VQ>? NE\SN3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK2PVc2QSd-Mk[yOlk4PTl:L3G+
CaES-17 NXjiZ2drS3m2b4TvfIlkcXS7IFHzd4F6 NWfBOHlFOOLCk{G2NOKh|ryP MVu0POKhcA>? MWDJR|UxRTVwNdMgxtHDqDBwMjFOwG0> MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR5NE[5N{c,OjZ2N{S2PVM9N2F-
HKESC-2 NF22TopEgXSxdH;4bYNqfHliQYPzZZk> NX7OSHBiOOLCk{G2NOKh|ryP NWC1O5RPPDkEoHi= M3n2c2lEPTB;NT64xsDDucLiMD61JO69VQ>? MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR5NE[5N{c,OjZ2N{S2PVM9N2F-

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
VEGFR-1 / NRP-1 ; 

PubMed: 18790786     


HT29 cells were treated with oxaliplatin (0.2 and 2 μmol/L) in 1% MEM-FBS. Western blotting analysis showed that oxaliplatin treatment up-regulated VEGFR-1 and NRP-1 protein expression. 

p-AKT(Ser473) / AKT / PTEN / p-Src(Tyr416); 

PubMed: 18790786     


HT29 cells were treated with oxaliplatin for 5, 15, 30, and 60 min. Western blotting showed that oxaliplatin induced Akt activation, with peak phosphorylation occurring at 60 min and decreased PTEN. Phospho-Src increased at 30 min.

p-Src(Y418) / p-FAK(Y861) ; 

PubMed: 19383922     


Src and FAK activation by Western blots were determined at various time periods after oxaliplatin treatment (2.5 µM) for HT29 and KM12-L4 cells, and representative of triplicate experiments. Densitometry represents a ratio of the phosphorylated form to th䲧疝Ỵ疞㧀疜膉痘 瘿⟸෕ᾰƌ෕Ð 㺣痖帉痖Ѐ

18790786 19383922
Immunofluorescence
E-cadherin / Vimentin; 

PubMed: 30787271     


Silencing ATXN2L reversed oxaliplatin-induced epithelial mesenchymal transition in MGC803 cells.

ATXN2L / G3BP1; 

PubMed: 30787271     


Under different concentrations and durations of oxaliplatin stimulation, the immunfluorescence staining expressions of ATXN2L and G3BP1 were enhanced by different levels, and ATXN2L coexpressed with G3BP1 in stress granules. 

30787271
Growth inhibition assay
Cell viability ; 

PubMed: 28339092     


Cell viability curve of BGC-823 and MKN-28 cells treated with oxaliplatin at different concentrations. 

28339092
In vivo

A weekly i.p. injection of Oxaliplatin at 10 mg/kg to nude mice bearing hepatocellular HCCLM3 tumors significantly reduces tumor volume and apoptotic index. [6] Oxaliplatin (5mg/kg, i.v. on days 1, 5 and 9) is active on T-leukemia-lymphoma L40 AKR with T/C of 1.77. Oxaliplatin is also efficient on intracerebrally grafted L1210 leukemia, MA 16-C xenografts, B16 melanoma xenografts, Lewis lung xenografts and C26 colon carcinoma xenografts. [7] Oxaliplatin induces impairment of retrograde neuronal transport in mice. [8]

Protocol

Cell Research:

[4]

- Collapse
  • Cell lines: RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2 and HT-144 cell lines
  • Concentrations: ~100 μM
  • Incubation Time: 48 hours
  • Method:

    The cytotoxicity studies are carried out with the sulforhodamine-B microculture colorimetrie assay. Typically, cells are plated into 96-well plates on day 0 and exposed to Oxaliplatin on day 1; the sulforhodamine-B assay is carried out 48 h after Oxaliplatin exposure. The plates are incubated at 37 °C in 5% CO2 and 100% relative humidity at all times except when adding Oxaliplatin and during the final assay period. The initial number of cells plated for the assay ranged from 2-20 × 103 cells/50 /nL/well. The numbers of cells for plating and the drug exposure time are based on pilot studies using the criteria that (a) the cells in control wells are still in the log phase of growth on the day of the assay; (b) the maximum absorbance for the untreated controls on the day of the assay is in the range of 1.0 to 1.5; and (c) cells go through >2 doublings during the drug exposure. Eight wells are used per concentration. The plates are read at 570 and/or 540 nm using a Biotek Instruments model EL309 microplate reader interfaced with an IBM PC-compatible computer. The data are transferred and transformed into a LOTUS 1-2-3 format by the computer program DATALOG, and survival fractions are calculated by comparing the drug treated with control


    (Only for Reference)
Animal Research:

[6]

- Collapse
  • Animal Models: Human hepatocellular carcinoma xenografts HCCLM3
  • Dosages: 10 mg/kg
  • Administration: A weekly i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro Water 3 mg/mL warmed (7.55 mM)
DMF Insoluble
Ethanol ''0.01 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 397.29
Formula

C8H14N2O4Pt

CAS No. 61825-94-3
Storage 2 years 4°C(in the dark) powder
Synonyms L-OHP, Eloxatin
Smiles C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05025826 Not yet recruiting Other: Phycocare|Other: Placebo Metastatic Gastric Cancer Nantes University Hospital|Algosource November 5 2021 Not Applicable
NCT05031975 Not yet recruiting Drug: Irinotecan|Drug: Temozolomide Colorectal Cancer Fondazione IRCCS Istituto Nazionale dei Tumori Milano November 1 2021 Phase 2
NCT04944550 Recruiting -- Upper Urinary Tract Urothelial Carcinoma|Nephroureterectomy|Tumor|Xenograft Model Centre Hospitalier Universitaire de Nīmes|INSERM U1194 Institut de Recherche en Cancérologie de Montpellier Campus Val d''Aurelle 34298 Montpellier cedex 5 March 1 2021 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is it ok to dissolve Oxaliplatin in DMSO?

  • Answer:

    Even though cis-platin is soluble in DMSO, the use of DMSO to dissolve cis– or trans-diamminedichloroplatinum (DDP) in biological studies is strongly discouraged. The DMSO inserts itself into the ligand and inactivates platin-containing compounds. DMF is a much better choice than DMSO.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Oxaliplatin (NSC 266046) | Oxaliplatin (NSC 266046) supplier | purchase Oxaliplatin (NSC 266046) | Oxaliplatin (NSC 266046) cost | Oxaliplatin (NSC 266046) manufacturer | order Oxaliplatin (NSC 266046) | Oxaliplatin (NSC 266046) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID